FP7H2020HORIZON
Centre Hospitalier Universitaire de Nantes
- Country
- FRFrance
- Defence projects
- 0
- Projects, all programmes
- 20
- As coordinator
- 1
- EU contribution (CORDIS)
- EUR 10,960,148
- Active
- 2008 to 2025
Projects
20 projects, newest first
| Project | Programme | Year | Role | EU contribution |
|---|---|---|---|---|
| PanCare4AYAPatient-centred, evidence-based late effect screening and follow-up care of survivors of adolescent and young adult cancer | HORIZON | 2025 | Third party | Not stated |
| BREATHBRinging hEAlTH and social sciences to a new level through an interdisciplinary doctoral programme | HORIZON | 2025 | Associated partner | EUR 0 |
| Homi-lungLong-term alterations of host-microbiome interactions and cardiovascular and respiratory diseases progression after pneumonia | HORIZON | 2024 | Participant | EUR 914,013 |
| MULTIRMULti-Tumour based prediction and manipulation of Immune Response | HORIZON | 2024 | Participant | EUR 300,838 |
| NaV1.5-CAREDNaV1.5 regulation fine-tuning as a therapy for cardiac Conduction and Arrhythmic diseases at Risk of suddEn Death | HORIZON | 2023 | Participant | EUR 178,164 |
| AIDAAn Artificially Intelligent Diagnostic Assistant for gastric inflammation | HORIZON | 2023 | Participant | EUR 453,595 |
| HAP2Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia | H2020 | 2020 | Coordinator | EUR 4,374,898 |
| RESHAPEReshaping undesired Inflammation in challenged Tissue Homeostasis by Next-Generation regulatory T cell (Treg) Approaches – from Advanced Technology Developments to First-in-Human Trials | H2020 | 2019 | Participant | EUR 5,000 |
| EU-TRAINThe EUropean TRAnsplantation and INnovation (EU-TRAIN) consortium for improving diagnosis and risk stratification in kidney transplant patients | H2020 | 2018 | Participant | EUR 891,366 |
| MAXIBONEPersonalised maxillofacial bone regeneration | H2020 | 2018 | Participant | EUR 160,781 |
| RESPINEREgenerative therapy of intervertebral disc: a double blind phase 2b trial of intradiscal injection of mesenchymal stromal cells in degenerative disc disease of the lomber SPINE unresponsive to conventional therapy | H2020 | 2017 | Participant | EUR 307,853 |
| Digi-NewBNon-invasive monitoring of perinatal health through multiparametric digital representation of clinically relevant functions for improving clinical intervention in neonatal units (Digi-NewB) | H2020 | 2016 | Third party | Not stated |
| BETA3_LVHA multi-center randomized, placebo-controlled trial of mirabegron, a new beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease | H2020 | 2015 | Participant | EUR 250,563 |
| TRANSLINKDefining the role of xeno-directed and autoimmune events in patients receiving animal-derived bioprosthetic heart valves | FP7 | 2013 | Participant | EUR 787,216 |
| BIO-DrIMPersonalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation | FP7 | 2012 | Participant | EUR 500,000 |
| SYSCLADSystems prediction of Chronic Lung Allograft Dysfunction | FP7 | 2012 | Participant | EUR 848,700 |
| TRIADTolerance Restoration In Autoimmune Diseases by selective manipulation of the CD28 costimulatory pathway | FP7 | 2012 | Participant | EUR 162,979 |
| THE ONE STUDYA Unified Approach to Evaluating Cellular Immunotherapy in Solid Organ Transplantation | FP7 | 2010 | Participant | EUR 678,000 |
| REBORNERegenerating Bone defects using New biomedical Engineering approaches | FP7 | 2010 | Participant | EUR 99,892 |
| LOULLA&PHILLADevelopment of 6-mercaptopurine and Methotrexate oral liquid formulations for the maintenance treatment of Acute Lymphoblastic Leukæmia in children | FP7 | 2008 | Participant | EUR 46,291 |
The country is the one the source records for the organisation’s registration (its PIC), and each profile says what it rests on. Where the record contradicts itself (the address in one country, the site name and the VAT number in another) we follow the two that agree: the Spanish research council CSIC is shown under Spain although its address is recorded in Italy. A body with sites in several countries is shown under the first of them in alphabetical order, and its profile lists the others. Beyond that we do not guess.
Where this comes from
- CORDIS: EU research projects (Horizon Europe, Horizon 2020, FP7)Last read on . Licence: Commission Decision 2011/833/EU (reuse of Commission documents). Source: CORDIS, European Commission.Participants and amounts as the Commission's CORDIS database states them (reuse under Commission Decision 2011/833/EU).
EU contribution is the amount CORDIS's open data pays to the participant. For a participant with linked third parties it may include their share (the CORDIS page prints the net); an amount the data does not hold is left out, not counted as zero. EDF factsheets state none per participant, so EDF projects count as projects but add nothing to the amounts.
Organisation-level facts only: a name, a country, a role, an amount, a year. A participant is recognised by its PIC where the source gives one, otherwise by name; the page says which. How the data is built.
Names are as CORDIS and the EDF project factsheets publish them. We do not list an organisation whose name looks like a natural person’s. If this entry is you, or a business named after you, and you want it removed, write to the contact in the imprint; the privacy notice (sections 7 and 9) says how a request is handled.